Original Article

Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs)

Triptorelin in Obsessive-Compulsive Disorder

Abstract

Objective: Analog triptorelin is one of the effective agonists for the treatment of reproductive disorders, particularly prostate cancer. Due to results of previous studies, we hypothesized that obsessive-compulsive disorder (OCD can be effectively treated with the long-term administration of a gonadotropin-releasing hormone (GnRH) analog, namely triptorelin. The aim of this study was to evaluate the effectiveness of triptorelin injection in clients with OCD.

Method: This randomized single-blind clinical trial was performed on 30 clients with OCD who had a Yale-Brown score of > 17 after 8 weeks of treatment. The participants were randomly assigned into two groups of triptorelin and placebo. The clients in the intervention group were treated with Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, in addition to triptorelin three times a month for at least 8 weeks. Clients in the control group received injection of distilled water as placebo three times in addition to the routine treatment. The outcome was evaluated by Yale-Brown OCD scale (Y-BOCS) at the baseline, as well as 4, 8, and, 20 weeks after the end of the treatment.

Results: The mean scores of Y-BOCS in the intervention and control groups was 30.5 ±67.6 and 30.5 ±67.6, respectively, before intervention, indicating no significant difference between the two groups (P = 0.0.8). The comparison of Y-BOCS scores after the intervention showed a significant difference between the two groups in the scores 4 (P = 0.01), 8 (P < 0.005), and 20 (P < 0.005) weeks after the treatment. With regards to the side effects of the medicine, 6.7% (n = 1) of the clients in the control group developed headache and 66.7% (n = 10) had late period in intervention group. The results revealed a significant difference between the two groups in terms of side effects (P < 0.005).

Conclusion: The results of this study showed triptorelin decreased the symptoms of OCD. The effectiveness of triptorelin in the treatment of symptoms in clients with OCD was confirmed in our study. However, due to the limited research addressing this domain, future studies are suggested to clarify this conclusion.

Burguière E, Monteiro P, Mallet L, Feng G, Graybiel AM. Striatal circuits, habits, and implications for obsessive-compulsive disorder. Curr Opin Neurobiol. 2015;30:59-65.
2. Grant JE, Mooney ME, Kushner MG. Prevalence, correlates, and comorbidity of DSM-IV obsessive-compulsive personality disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Psychiatr Res. 2012;46(4):469-75.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Philadelphia: American Psychiatric Pub; 2013.
4. Rajabi GR. Validating of the Padua obsessive-compulsion inventory in freshman students of Shahid Chamran University of Ahvaz. J Fundamentals Mental Health. 2007;9(33-34):43-52.
5. Sadock BJ, Sadock VA. Kaplan and Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. Philadelphia: Lippincott Williams & Wilkins; 2011.
6. Adam Y, Meinlschmidt G, Gloster AT, Lieb R. Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Soc Psychiatry Psychiatr Epidemiol. 2012;47(3):339-49.
7. Stern ER, Fitzgerald KD, Welsh RC, Abelson JL, Taylor SF. Resting-state functional connectivity between fronto-parietal and default mode networks in obsessive-compulsive disorder. PLoS One. 2012;7(5):e36356.
8. Fernandez-Egea E, Worbe Y, Bernardo M, Robbins TW. Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. Psychol Med. 2018;48(16):2668-75.
9. Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011;72(4):473-9.
10. Abramowitz JS, Baucom DH, Wheaton MG, Boeding S, Fabricant LE, Paprocki C, et al. Enhancing exposure and response prevention for OCD: a couple-based approach. Behav Modif. 2013;37(2):189-210.
11. Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011;31(2):174-9.
12. Palm U, Leitner B, Kirsch B, Behler N, Kumpf U, Wulf L, et al. Prefrontal tDCS and sertraline in obsessive compulsive disorder: a case report and review of the literature. Neurocase. 2017;23(2):173-7.
13. Joshi G, Mick E, Wozniak J, Geller D, Park J, Strauss S, et al. Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder. Bipolar Disord. 2010;12(2):196-204.
14. Isomura K, Brander G, Chang Z, Kuja-Halkola R, Ruck C, Hellner C, et al. Metabolic and Cardiovascular Complications in Obsessive-Compulsive Disorder: A Total Population, Sibling Comparison Study With Long-Term Follow-up. Biol Psychiatry. 2018;84(5):324-31.
15. Jairam J, van Marle HJ. [The treatment of hypersexuality in a male with obsessive compulsive disorder as psychiatric co-morbidity]. Tijdschr Psychiatr. 2008;50(2):113-7.
16. Eriksson T. Antiandrogenic treatment for obsessive-compulsive disorder. Am J Psychiatry. 2000;157(3):483.
17. Eriksson T. Use of composition comprising at least one substance within the group GnRH-analogues for treatment of obsessive-compulsive disorder (OCD). New York: United States Patent Application US; 2003.
18. Eriksson T. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin. Int Clin Psychopharmacol. 2007;22(1):57-61.
19. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev. 1997;18(2):180-205.
20. Agrawal A, Heath AC, Lynskey MT. DSM-IV to DSM-5: the impact of proposed revisions on diagnosis of alcohol use disorders. Addiction. 2011;106(11):1935-43.
21. Esfahani SR, Motaghipour Y, Kamkari K, Zahiredin A, Janbozorgi M. Reliability and Validity of the Persian Version of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Iranian Journal of Psychiatry & Clinical Psychology. 2012;17(4).
22. Guglielmi V, Vulink NC, Denys D, Wang Y, Samuels JF, Nestadt G. Obsessive-compulsive disorder and female reproductive cycle events: results from the OCD and reproduction collaborative study. Depress Anxiety. 2014;31(12):979-87.
23. Peterson BS, Zhang H, Anderson GM, Leckman JF. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. J Clin Psychopharmacol. 1998;18(4):324-31.
24. Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosc. 2010;12(2):187-97.
25. Kadar T, Telegdy G, Schally AV. Behavioral effects of centrally administered LH-RH agonist in rats. Physiol Behav. 1992;51(3):601-5.
26. Umathe S, Bhutada P, Dixit P, Shende V. Increased marble-burying behavior in ethanol-withdrawal state: modulation by gonadotropin-releasing hormone agonist. Eur J Pharmacol. 2008;587(1-3):175-80.
27. Saleem R, Kaitiff D, Treasaden I, Vermeulen J. Clinical experience of the use of triptorelin as an antilibidinal medication in a high-security hospital. J Forensic Psychiatry Psychol. 2011;22(2):243-51.
28. Ho DK, Kottalgi G, Ross CC, Romero-Ulceray J, Das M. Treatment with triptorelin in mentally disordered sex offenders: experience from a maximum-security hospital. J Clin Psychopharmacol. 2012;32(5):739-40.
Files
IssueVol 16 No 4 (2021) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijps.v16i4.7232
Keywords
Gonadotropin-Releasing Hormone Obsessive Compulsive Disorder Triptorelin

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Nikzad F, Sadjadi SA, Mohammadpour AH, Ziaee M, Behdani F, Naghibi SM, Nejatifard SN, Ghanbari M, Akhondpour Manteghi A. Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs). Iran J Psychiatry. 2021;16(4):444-450.